Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News enVVeno Medical Corp NVNO

enVVeno Medical Corporation is a late-stage clinical med-tech company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:NVNO)

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

Accesswire 3 days ago

Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024 Vascular Annual Meeting

Accesswire 7 days ago

New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024

Accesswire 11 days ago

enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update

Accesswire May 8, 2024

Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium

Accesswire April 24, 2024

New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024

Accesswire April 16, 2024

enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer

Accesswire April 9, 2024

enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity

Accesswire March 15, 2024

Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting

Accesswire March 6, 2024

Opinion & Analysis (NDAQ:NVNO)

Texas Heart Takes to the CoreoGraft

Streetwise Reports October 11, 2018

Bullboard Posts (NDAQ:NVNO)

FDA LIFT-OFF

Looks like positive results are on the verge of better days ahead for both patients and investors. 
Teccing - March 9, 2024

HJLI ..... N.L.O.D

Sonnamabeotch
Iseneschal - August 3, 2021

HJLI ...what can I say?

F&%K !!!!!!!!!!!! Stopped out
Iseneschal - August 3, 2021

HJLI ...... Paytience is needed

I see double digits
Iseneschal - August 3, 2021

HJLI .... 1st time thru DTL today

on the Pullback from h.o.d. Just sayin...there could be some fireworks left in this Volume needs a jump start.  Cheers 
Iseneschal - August 3, 2021

RE:HJLI...... bouncing now ...watch for volume spike

 Volume is increasing...waiting for some major buying pressure.  Cheers !
Iseneschal - August 3, 2021